Clinical Trial Update: Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on sequential administration of WJ-MSCs for graft-versus-host disease refractory to second-line treatment (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• WJ-MSCs (mesenchymal stromal cells from Wharton's jelly)

Snippet

Sponsor: Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | Conditions: Graft Versus Host Disease | Phase 1, Phase 2 | Status: UNKNOWN